BPC-157 + TB500 20mg: How a Combination Vial Is Specified
Combination vials that list two peptides and a single total mass—such as a "BPC-157 + TB-500 20mg" label—raise specification questions that a single-peptide vial does not. Researchers comparing suppliers need to know exactly how that 20mg figure is divided, verified, and documented before it factors into any dilution or concentration calculation. This article walks through how a blended vial is specified on paper, not how it should be used.
Why Blended Vials Need Different Specs
A single-peptide vial of BPC-157 is specified against one reference standard, one molecular weight, and one chromatographic trace. A vial labeled "BPC-157 + TB-500 20mg" introduces a second peptide entity into the same lyophilized cake, which means the specification has to account for two distinct identities, two purity figures, and a declared split of total mass between them. For a laboratory researcher building a stock solution for in vitro work, the difference matters because a molar concentration calculation for one peptide in the mixture depends on knowing how much of the 20mg actually belongs to that peptide, not simply dividing by two.
TB-500 refers to the synthetic fragment derived from Thymosin Beta-4, and in combination products it is almost always this fragment rather than the full-length protein. Suppliers that are precise about specification will state this explicitly on the label or in supporting documentation rather than leaving "TB-500" to be inferred.
How the 20mg Figure Is Split
In most combination vials on the research market, the total declared mass is split evenly — 10mg of each peptide contributing to the labeled 20mg — but this is a convention, not a rule enforced by any regulatory body. Some suppliers manufacture combination vials at a 2:1 or 1:2 ratio and simply note it in smaller text or in the product description rather than the headline label. This is the single most important number for a researcher to confirm before any calculation is made, because:
- A 10mg/10mg split yields a different molar ratio than a 15mg/5mg split, since the two peptides have different molecular weights
- Concentration calculations for each peptide independently require the per-peptide mass, not the vial total
- Lot-to-lot consistency in the ratio is not guaranteed unless the supplier states it is manufactured to a fixed specification, not blended per batch by volume
A specification sheet that only states "20mg total peptide content" without breaking out the per-component mass is incomplete for research purposes and should prompt a direct inquiry to the supplier before use in any quantitative protocol.
What a Combination COA Actually Covers
A Certificate of Analysis for a blended vial should report results for each peptide separately, not as a combined purity average. A single purity percentage covering "total peptide content" obscures whether one component is significantly less pure than the other, which matters if a researcher is isolating the effect of one peptide using the vial as a source material. A properly scoped combination COA includes:
| COA Element | Single-Peptide Vial | Combination Vial (Adequate Spec) |
|---|---|---|
| Purity (HPLC) | One value | Separate value per peptide |
| Mass per vial | Single figure, e.g. 5mg | Per-component figures summing to labeled total |
| Identity confirmation | One MS trace | Two distinct MS traces or a resolved co-elution report |
| Molecular weight reference | Single value | Both reference MWs listed |
| Lot number | One lot | One lot for the blended vial, referencing source lots for each peptide where available |
If a supplier cannot produce separate purity figures for each peptide in a blend, that is a meaningful gap in the documentation, not a cosmetic one.
Identity Testing for Two Peptides in One Vial
Mass spectrometry identity confirmation becomes more involved in a combination vial because the analyst has to resolve two distinct mass signatures from a single lyophilized sample rather than confirming one expected mass against one reference. BPC-157 and the TB-500 fragment have different molecular weights, so a well-run analysis should show two clearly separated peaks on HPLC and two corresponding mass signatures on MS, rather than a single broad peak that is assumed to contain both. A combination COA that shows only one chromatographic trace for a two-peptide vial has not actually demonstrated that both components are present at their stated identity and mass — it has demonstrated that something eluted.
Documentation Checklist Before Ordering
Before a combination vial factors into a research budget or protocol design, the following documentation should be requested or confirmed from the supplier's product page and COA:
- Explicit per-component mass split (e.g., 10mg/10mg, not just "20mg total")
- Separate HPLC purity values for each peptide
- Separate mass spectrometry identity confirmation for each peptide
- Confirmation of which TB-500 form is used — fragment versus full-length sequence
- Lot number traceable to a dated COA, not a generic specification sheet reused across batches
- Storage and stability notes specific to the lyophilized blend, since co-lyophilized peptides can behave differently in storage than either peptide alone
Common Labeling Errors to Watch For
A handful of labeling patterns show up repeatedly in combination products across the research peptide market and are worth flagging specifically:
A combination vial is a convenience format for researchers running protocols that call for both peptides, but the convenience only holds up if the underlying specification is as rigorous, component by component, as a standalone vial would be. Treating the label's total mass as a usable number without confirming the split defeats the purpose of having a COA at all.